CPAP therapy shows no significant reduction in cancer incidence among obstructive sleep apnea patients

A meta-analysis pooled data from three randomized controlled trials (SAVE, RICCADSA, ISAACC) involving patients with obstructive sleep apnea. The analysis compared cancer incidence between those receiving continuous positive airway pressure therapy and control groups, using adverse event data from trials not primarily designed to assess cancer outcomes.

The primary finding was no statistically significant difference in cancer incidence between CPAP and control groups, with a confidence interval of 0.55 to 1.68 that crosses 1.0. The effect size, absolute numbers, and p-value were not reported. Safety and tolerability data specific to this analysis were not reported.

Key limitations include that the trials were not designed with cancer as a primary outcome, and the confidence interval is wide, indicating substantial uncertainty. The analysis does not provide evidence that CPAP therapy reduces cancer risk in OSA patients. Clinicians should continue to focus on established benefits of CPAP for sleep apnea management rather than cancer prevention.